Implement the 2020 AUA guideline recommendations for the evaluation of microscopic hematuria into clinical practice
Recognize and develop an approach to managing upper and lower urinary tract bleeding
Apply a stepwise strategy for treating refractory hemorrhagic cystitis
Hematuria represents one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation and strategies for management of hematuria is critical. This course is designed to use a case-oriented format to provide a guidelines-based approach to the evaluation and management of hematuria. Target audience includes practicing urologists and advanced practice providers (APPs), as well as residents and fellows. Specifically, in attending the course participants will obtain an in-depth understanding of the updated 2020 AUA guideline recommendations for the initial evaluation of patients with asymptomatic microscopic hematuria, as well as the evidence supporting these recommendations. Other national and organizational guidelines will be reviewed as well, and disparate health system implications including cost and efficiency of delivery will be discussed. Recommendations for follow-up of these patients, as well as future opportunities for further refining the approach to microhematuria evaluation, will also be covered. In addition, the course will include a discussion of the management of frequently-encountered clinical challenges in renal and upper tract bleeding, as well as persistent benign prostatic hyperplasia (BPH)-related bleeding. Detailed information will be provided regarding a stepwise approach to the management of patients with hemorrhagic cystitis, including intravesical treatment regimens and associated side effect profiles. Additionally, data will be reviewed supporting treatments for refractory hemorrhagic cystitis, including hyperbaric oxygen and urinary diversion.